Navigation Links
ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development
Date:9/15/2011

SHANGHAI, Sept. 15, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, and Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui"), a leading Chinese pharmaceutical company, today announced that Shanghai ChemPartner ("ChemPartner"), a wholly owned subsidiary of ShangPharma, and Hengrui have entered into a strategic partnership for the development of novel therapeutic monoclonal antibodies ("mAbs").

Through the partnership, ChemPartner and Hengrui will initially collaborate on the development of novel therapeutic mAbs in a major therapeutic area. ChemPartner will head pre-clinical research activities, including target protein preparation and assay system establishment, generation and optimization of lead antibodies, as well as pharmacokinetic and preformulation studies, while Hengrui will lead drug development for the mAb. Following the project's completion, Hengrui will retain the intellectual property rights of the mAb and any patents related to the mAb's development. The first program will have several preclinical and development milestone payments, as well as a timeline-based incentive payment.

Mr. Michael Xin Hui, chairman and chief executive officer of ShangPharma, commented, "Hengrui is the first major domestic pharmaceutical company to form such an antibody partnership with ChemPartner, and the program is the first of its kind in China. The indication and market potential for the first mAb is very broad. We are proud to be working with Hengrui, one of the major domestic pharmaceutical companies. We expect our collaborative work will lead to further domestic and multinational partnerships in biologics development, and pave the way for innovation and growth in China's own biotechnology industry."

Dr. Lianshan Zhang, Hengru
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ShangPharma Announces Second Quarter 2011 Results
2. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise
3. ShangPharma Announces First Quarter 2011 Results
4. ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011
5. ImaginAb, Inc. Announces Formation of Singapore Subsidiary, ImaginAb Molecular Imaging Pte Ltd.
6. Infrared Systems Internationals Subsidiary, AquaLiv Inc., Explains Its Revolutionary Technology in Laymans Terms
7. Infrared Systems Internationals Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS
8. AquaStar Holdings, Inc. Subsidiary Appoints Former Beckman Coulter Executive as Vice President of Operations
9. New England Biolabs Opens New Subsidiary Office in France
10. Beijing Chaoyang District Court Grants Investigation Letters Against Inverness Medical Beijing, A Subsidiary of Alere Inc.
11. China Cord Blood Corporation Forms Zhejiang Subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015   GenoSpace ... for the interpretation and analysis of genomic and ... Fischer has joined the company as Vice ... - http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace ... to integrate, interpret, analyze and explore complex sets ...
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report on the ... state of the global Propanol market with a focus on the Chinese situation. Major ... Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
(Date:7/30/2015)... July 30, 2015   Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... today reported financial results for the second quarter 2015. ... 2015, we remain on track to achieve our commercial ... Executive Officer of the Company. "Since our last quarterly ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... Md., Oct. 1 Novavax, Inc. (Nasdaq: NVAX ... the board,s corporate governance, compensation and finance committees, replacing board ... James Tananbaum who is retiring from the board. Mr. ... immunology products companies and joined the Novavax board in June ...
... Oct. 1 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) ... and affordable vaccines based on proprietary manufacturing technologies ... has initiated a Phase I human clinical trial ... Enrolment is ongoing and vaccination has commenced. The ...
... ... Administration (USFDA) will host Assessing Benefits and Risks of Medicinal Products in Regulatory Decisions from ... ... (DIA) and the US Food and Drug Administration (USFDA) will host Assessing Benefits ...
Cached Biology Technology:Novavax Announces Board of Director Changes 2Novavax Announces Board of Director Changes 3Medicago begins human clinical testing with its avian flu pandemic vaccine 2Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop 2Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop 3
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/20/2015)... 2015  Acuity Market Intelligence,s latest research "The ... Commerce and Privacy" forecasts that between 2014 and ... be downloaded to smart mobile devices by 2.2 ... is projected to generate more than $67.9 billion ... forecast period.    "Biometrics is at ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/188684 for BEHAVIORAL-DIRECTED ... another new convenient and secure method to make ... innovative payment methods, introduced with its groundbreaking voice-direct ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... three-dimensional plasmon rulers, capable of measuring nanometer-scale spatial ... researchers with the U.S. Department of Energy (DOE),s ... with researchers at the University of Stuttgart, Germany. ... unprecedented details on such critical dynamic events in ...
... awarded the University of Colorado Boulder a six-year, ... long-term ecological changes in Colorado,s high mountains, both ... Awarded to CU-Boulder,s Institute of Arctic and Alpine ... students, including undergraduates, to continue key environmental studies ...
... upon previous efforts producing a high-quality de ... E. coli O104:H4 outbreak ... their collaborators at the University Medical Centre ... map of the genome and plasmids without ...
Cached Biology News:Taking the 3-D measure of macromolecules: 2Taking the 3-D measure of macromolecules: 3NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 2NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 3NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 4The complete map of the Germany E. coli O104 genome released 2
... Lipid adsorption and clarification reagent; ... the purification of antibodies, proteins, nucleic ... has negligible cross-reactivity, and improves downstream ... a solid-phase, non-ionic adsorbent supplied as ...
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
... incubator-shaker, has the smallest footprint of all our ... x 680 mm (W x D) does not ... x 510mm). Available in 25 mm or 50 ... shaking applications requiring controlled speed and temperature ...
Request Info...
Biology Products: